Funding for this research was provided by:
Bill & Melinda Gates Foundation (OPP1017459)
European and Developing Countries Clinical Trials Partnership (IP.2007.32011.011)
Received: 28 March 2017
Accepted: 10 October 2017
First Online: 24 November 2017
Ethics approval and consent to participate
: The ethics committee at University College London (London, UK) and all national and local ethics committees approved the trial, including these analyses, which were planned as a secondary objective to the trial. For a full list of ethics committees, see Additional file InternalRef removed. All patients provided written or witnessed oral informed consent.
: Not applicable.
: CMM is an employee of the Global Alliance for TB Drug Development, which is a non-profit organisation that funded this work and receives funding from governments and charities. SHG reports grants from the Innovative Medicines Initiative (IMI) PreDiCT-TB, during the conduct of the study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.